Document Detail


Gastrointestinal Effects of the Addition of Ascorbic Acid to Aspirin.
MedLine Citation:
PMID:  22151399     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin, have been associated with the damage to the gastrointestinal tract. One proposed mechanism of injury to the gastrointestinal mucosa by NSAIDs is oxygen radical-dependent microvascular injury. There is reasonable evidence to support the benefit of the addition of ascorbic acid, an ingredient with antioxidant properties, to moderate the adverse gastrointestinal (GI) effects of aspirin. Pharmacokinetic data have demonstrated that aspirin and ascorbic acid combination therapy can assist in mitigating the decrease in levels of ascorbic acid secondary to aspirin monotherapy. Endoscopic evaluation has demonstrated that the addition of ascorbic acid to aspirin significantly improves Lanza scores and rates of blood loss when compared to aspirin administration alone. When taken with ascorbic acid, the patient-reported tolerability of aspirin has been shown to be comparable to paracetamol and placebo. The existing body of evidence is relevant to short-term therapy with analgesic aspirin doses, and extrapolation to long-term therapy with low-dose aspirin is not appropriate. The purported benefit of an aspirin and ascorbic acid combination is a local observance and is not suspected to influence the adverse GI effects experienced as a result of systemic prostaglandin inhibition. Nevertheless, ascorbic acid may be a viable addition to the strategies employed to improve the gastrointestinal tolerability of aspirin.
Authors:
Vrunda Patel; Matt Fisher; Michael Voelker; Uwe Gessner
Related Documents :
17726749 - Effect of chlorogenic acid on antioxidant activity of flos lonicerae extracts.
11410009 - Effect of various domestic processing methods on antinutrients and in vitro protein and...
14985189 - Characterization of phenolic compounds in some indian mango cultivars.
1614999 - Teas and tea components as inhibitors of carcinogen formation in model systems and man.
17367679 - Can phenolic compounds be used for the protection of corn from fungal invasion and myco...
12820389 - Inhibition of no production by activated macrophages by phenolcarboxylic acid monomers ...
18970689 - Determination of carbofuran in water by homogeneous immunoassay using selectively conju...
383289 - Mutagenicity of the naturally occurring carcinogen cycasin and synthetic methylazoxymet...
17726749 - Effect of chlorogenic acid on antioxidant activity of flos lonicerae extracts.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-12-7
Journal Detail:
Title:  Pain practice : the official journal of World Institute of Pain     Volume:  -     ISSN:  1533-2500     ISO Abbreviation:  -     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-12-13     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101130835     Medline TA:  Pain Pract     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2011 The Authors. Pain Practice © 2011 World Institute of Pain.
Affiliation:
Bayer HealthCare, Morristown, New Jersey, U.S.A. Bayer HealthCare, Leverkusen, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Use of zero-valent iron biosand filters to reduce Escherichia coli O157:H12 in irrigation water appl...
Next Document:  Treatment of Chronic Pain in Failed Back Surgery Patients with Spinal Cord Stimulation: a Review of ...